

MINIREVIEW

Plasmid-Determined AmpC-Type β -Lactamases

Alain Philippon,¹ Guillaume Arlet,² and George A. Jacoby^{3*}

Service de Bactériologie, Université Paris V—Hôpital Cochin,¹ Service de Bactériologie, Hôpital Tenon,² Paris, France, and VA Medical Center, Bedford, and Lahey Clinic, Burlington, Massachusetts³

The predominant mechanism for resistance to β -lactam antibiotics in gram-negative bacteria is the synthesis of β -lactamase. To meet this challenge, β -lactams with greater β -lactamase stability, including cephalosporins, carbapenems, and monobactams, were introduced in the 1980s. Resistance appeared initially in organisms such as *Enterobacter cloacae*, *Citrobacter freundii*, *Serratia marcescens*, and *Pseudomonas aeruginosa* that could, by mutation, overproduce their chromosomal AmpC (also termed class C or group 1) β -lactamase, thus providing resistance to both oxyimino- and 7- α -methoxy-cephalosporins and monobactams (74).

Later, resistance appeared in bacterial species that lack an inducible AmpC enzyme, such as *Klebsiella pneumoniae*, *Escherichia coli*, *Salmonella* spp., and *Proteus mirabilis*, and this resistance was found to be mediated by plasmids encoding extended-spectrum β -lactamases (ESBLs), which are enzymes that arose by mutations in TEM or SHV β -lactamases of more limited hydrolytic capacity (39, 40, 68). Such resistance included oxyimino-cephalosporins and monobactams but not 7- α -methoxy-cephalosporins and was blocked by clavulanate, sulbactam, or tazobactam, which are inhibitors that are generally ineffective against class C enzymes (49, 75).

With continuing use of 7- α -methoxy-cephalosporins (cefoxitin and cefotetan) and the clinical introduction of β -lactamase inhibitor combinations (clavulanate with amoxicillin or ticarcillin, sulbactam with ampicillin, and tazobactam with piperacillin), plasmids encoding class C β -lactamases appeared (56). Like their counterpart on the chromosome, such enzymes provided a broader spectrum of resistance than ESBLs and were not blocked by commercially available inhibitors.

Furthermore, in a strain with decreased outer membrane permeability such enzymes can provide resistance to carbapenems as well, as has been observed with clinical isolates of *K. pneumoniae* during an outbreak in New York (13) and in individual isolates of *E. coli* in the United Kingdom (78) and of *K. pneumoniae* in Sweden (17).

HISTORY

AmpC β -lactamases, demonstrated or presumed to be chromosomally mediated, have been described in *Acinetobacter* spp., *Aeromonas* spp., *Chromobacterium violaceum*, *C. freundii*, *Enterobacter* spp., *E. coli*, *Hafnia alvei*, *Lysobacter lactamgenus*,

Morganella morganii, *Ochrobactrum anthropi*, *Proteus rettgeri*, *Providencia stuartii*, *P. aeruginosa*, *Psychrobacter immobilis*, *Rhodobacter sphaeroides*, *S. marcescens*, and *Yersinia enterocolitica*. In many genera, AmpC is inducible via a system involving *ampD*, *ampG*, *ampR*, and intermediates in peptidoglycan recycling (38, 86). The *ampC* gene of *E. coli* is normally expressed at a low level, regulated by a growth rate-dependent attenuation mechanism (42) but not by induction, since *ampR* is missing (35). In *Shigella flexneri* and *Shigella dysenteriae*, *ampC* is included in a large deletion (55). An *ampC* locus appears on the genetic map of *Salmonella* (76), but the evidence for its existence was indirect and its presence has not been confirmed in the sequenced genomes of *Salmonella enterica* serotypes Typhimurium or Paratyphi (57), so that *Salmonella* is considered to be AmpC[−] (56). A chromosomal *ampC* gene is also lacking in *Klebsiella* spp. (57) and *P. mirabilis*.

In 1976, Bobrowski et al. described a plasmid-mediated β -lactamase indistinguishable from the AmpC enzyme of *E. coli* in a strain of *P. mirabilis* (11). Unfortunately, the original plasmid was lost, there was some doubt about the transfer experiments, and molecular studies were not done. In 1982, Levesque et al. reported a plasmid-mediated cephalosporinase in *Achromobacter* spp. (48). Regrettably, the original strain was lost, the β -lactamase gene was not sequenced, and in retrospect the biochemical properties of the enzyme resembled those of a group 2b broad-spectrum enzyme rather than of a group 1 cephalosporinase. In 1983, Knothe et al. reported the transfer of cefoxitin resistance from *S. marcescens* to *Proteus* or *Salmonella* spp., but resistance segregated on transfer to *E. coli* and no biochemical or molecular studies were done (44).

In 1989, Bauernfeind et al. described a *K. pneumoniae* isolate from South Korea that could transfer resistance to cefoxitin and cefotetan as well as to penicillins, oxyimino-cephalosporins, and monobactams to *E. coli* (6). The enzyme, termed CMY-1 for its cephamycinase activity, had an isoelectric point (pI) of 8.0 and was more sensitive to inhibition by sulbactam than by clavulanate or tazobactam, suggesting that it might be a class C enzyme. However, the first proof that a class C β -lactamase had been captured on a plasmid was provided by Papanicolaou et al., who described transmissible resistance to α -methoxy- and oxyimino- β -lactams mediated by an enzyme (MIR-1) with the biochemical properties of a class 1 β -lactamase and showed that part of the MIR-1 gene was 90% identical to the *ampC* gene of *E. cloacae* (65).

Subsequently, plasmid-mediated class C β -lactamases have been discovered worldwide (Table 1). They have been named

* Corresponding author. Mailing address: Lahey Clinic, 41 Mall Rd., Burlington, MA 01805. Phone: (781) 744-8608. Fax: (781) 744-1264. E-mail: george.a.jacoby@lahey.org.

TABLE 1. Chronology of discovery of AmpC plasmid-encoded β -lactamases^a

Name	Country ^b	Year ^c	Species	pI	Reference(s)
MIR-1	United States	1988	<i>K. pneumoniae</i>	8.4	41, 65
CMY-1	South Korea	1988	<i>K. pneumoniae</i>	8.0	6, 9
BIL-1	United Kingdom (Pakistan)	1989	<i>E. coli</i>	8.8	66, 88
FOX-1	Argentina	1989	<i>K. pneumoniae</i>	6.8–7.2	31
CMY-2	Greece	1990	<i>K. pneumoniae</i>	9.0	8
	France (Algeria)	1994	<i>Salmonella senftenberg</i>	9.0	46
MOX-1	Japan	1991	<i>K. pneumoniae</i>	8.9	36
DHA-1	Saudi Arabia	1992	<i>S. enteritidis</i>	7.8	26
	France	1998	<i>K. pneumoniae</i>	7.8	Verdet et al. ^d
DHA-2	France	1992	<i>K. pneumoniae</i>	7.8	24
FOX-2	Germany (Guatemala)	1993	<i>K. pneumoniae</i>	6.7	10
LAT-1	Greece	1993	<i>K. pneumoniae</i>	9.4	82, 83
FOX-3	Italy	1994	<i>K. oxytoca</i> , <i>K. pneumoniae</i>	7.25	51
LAT-2	Greece	1994	<i>K. pneumoniae</i> , <i>E. coli</i> , <i>E. aerogenes</i>	9.1	28
ACT-1	United States	1994	<i>K. pneumoniae</i> , <i>E. coli</i>	9.0	13
MOX-2	France (Greece)	1995	<i>K. pneumoniae</i>	9.2	Boyer-Mariotte et al. ^e
CMY-4	Tunisia	1996	<i>P. mirabilis</i>	9.2	85
	United Kingdom	1999 (P)	<i>E. coli</i>	>8.5	78
	Sweden (India)	1998	<i>K. pneumoniae</i>	9.0	17
ACC-1	Germany	1997	<i>K. pneumoniae</i>	7.7	7
	France (Tunisia)	1998	<i>K. pneumoniae</i>	7.8	60
	Tunisia	1997–2000	<i>K. pneumoniae</i> , <i>P. mirabilis</i> , <i>Salmonella</i> spp.	7.8	71
	France (Tunisia)	2000	<i>P. mirabilis</i> , <i>E. coli</i>	7.7	30
CMY-3 ^f	France	1998 (P)	<i>P. mirabilis</i>	9.0	14
LAT-3	Greece	1998 (P)	<i>E. coli</i>	8.9	29
LAT-4	Greece	1998 (P)	<i>E. coli</i>	9.4	29
CMY-8	Taiwan	1998	<i>K. pneumoniae</i>	8.25	91
CMY-5	Sweden	1999 (P)	<i>K. oxytoca</i>	8.4	89, 90
FOX-4	Spain	2000 (P)	<i>E. coli</i>	6.4	12

^a Other plasmid-mediated AmpC-type β -lactamases have been described in GenBank but are not yet published, including CMY-6, CMY-7, CMY-9, CMY-10, CMY-11, and FOX-5.

^b Country of isolation (if different, probable country of origin is indicated in parentheses).

^c Year of isolation or date of publication (P).

^d C. Verdet, N. Boutros, B. Salauze, A. Rossier, T. Lambert, A. Philippon, and G. Arlet. Abstr. 20th Réunion Interdisciplinaire Chimiothérapie Anti-Infectieuse, abstr. 24/C4, 2000.

^e S. Boyer-Mariotte, L. Raskine, B. Hanau, A. Philippon, M.M. Sanson-LePors, and G. Arlet, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C-7, 1998.

^f Chromosomal location.

with inconsistency typical of β -lactamase nomenclature according to the resistance produced to cephamycins (CMY), cefoxitin (FOX), and moxalactam (MOX) or latamoxef (LAT), to the type of β -lactamase, such as AmpC type (ACT) or Ambler class C (ACC), and to the site of discovery, such as the Miriam Hospital in Providence, R.I. (MIR-1) or Dhahran hospital in Saudi Arabia (DHA). BIL-1 was even named after the patient (Bilal) who provided the original sample (D. J. Payne, personal communication).

Increasingly, a demonstration of enzyme uniqueness relies on nucleotide sequencing, a sometimes imperfect technique. Barlow and Hall (M. Barlow and B. G. Hall, submitted for publication) recently reanalyzed several plasmid-mediated AmpC genes and concluded that the amino acid sequences of CMY-2, BIL-1, and LAT-2 were identical, as were LAT-1 and LAT-4 and also LAT-3 and CMY-6. In the text and tables below, the originally published names have been retained, with apparent identities in parentheses, such as BIL-1 (CMY-2).

EPIDEMIOLOGICAL FEATURES

As shown in Table 1, plasmid-mediated class C β -lactamases have been discovered most frequently in isolates of *K. pneumoniae* and also in other naturally AmpC⁺ species such as *K. oxytoca*, *Salmonella*, and *P. mirabilis*. Some enzymes have been

found in *E. coli*, although this species can also increase production of its normally weakly expressed chromosomal AmpC enzyme by gene duplication or mutation in the *ampC* promoter or attenuator with consequent enhanced gene expression (18, 62). In Greece, plasmid-mediated LAT-2 (CMY-2) has been found in clinical isolates of *Enterobacter aerogenes* simultaneously with its appearance in clinical strains of *K. pneumoniae* and *E. coli* (28), and in France plasmid-mediated ACC-1 has been found in both *E. coli* and *P. mirabilis* isolates obtained from the same urine sample (30). In the United States, ceftriaxone-resistant *Salmonella* have begun to appear that owe their resistance to plasmid-mediated CMY-2 β -lactamase. Between 1996 and 1998, 13 ceftriaxone-resistant *Salmonella* strains were isolated from symptomatic patients in eight different states (22). Several *Salmonella* serotypes were involved. Such strains have been isolated from cattle and pigs (87). One 12-year old boy living in Nebraska was infected with a ceftriaxone-resistant strain identical to *S. enterica* serotype Typhimurium strains isolated from his father's infected calves (23).

A striking feature is the global distribution of strains producing plasmid-determined cephalosporinases. They have been found in Africa (Algeria, Tunisia), Asia (India, Japan, Pakistan, South Korea), Europe (France, Germany, Greece, Italy, Sweden, United Kingdom), the Middle East (Saudi Arabia), North America (United States), and South and Central

America (Argentina, Guatemala) (Table 1). Just as with strains producing ESBLs such as SHV-2 or SHV-5 (77), travel and transfer of patients has allowed the importation of BIL-1 (CMY-2) from Pakistan to the United Kingdom (66), strains with BIL-1-like enzymes from the Indian subcontinent to London (59), several CMY types (CMY-2, CMY-6, CMY-7) from Punjab (India) to London (unpublished results), CMY-2 from Algeria to France (46), CMY-4 from India to Sweden (17), FOX-2 from Guatemala to Germany (10), ACC-1 from Tunisia to France (30, 60), and MOX-2 from Greece to France (S. Boyer-Mariotte, L. Raskine, B. Hanau, A. Philippon, M. M. Sanson-LePors, and G. Arlet, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C-7, 1998). CMY-2 is the most prevalent of the plasmid-mediated AmpC enzymes and the most widely distributed geographically, having been reported in Algeria, France, Germany, Greece, India, Pakistan, Taiwan, Turkey, the United Kingdom, and the United States (5).

Except for *Salmonella* strains and occasional *K. pneumoniae* isolates (43), most strains producing plasmid-determined AmpC enzymes have been isolated from patients after several days in the hospital. Affected patients have often had prolonged stays in intensive care units. Some patients had one or more surgical procedures (65), an underlying disease such as leukemia (78) or cancer (27, 36, 59), or were immunocompromised after liver or kidney transplantation (59). Sources of organisms included cultures of urine (about 50% of isolates), blood, wounds, sputum, or stool. Some isolates were recovered in mixed cultures with other potential pathogens. A majority of the patients had been treated with β -lactam antibiotics including cefoxitin, moxalactam, cefmetazole, cefotetan, or imipenem (13, 31, 36, 65). Many strains with plasmid-determined AmpC enzymes also produce TEM-1, TEM-2, or even an ESBL, such as SHV-5 (28, 29, 59).

As already observed for ESBL-producing *K. pneumoniae* organisms (15, 61, 72), AmpC-producing nosocomial isolates can be responsible for outbreaks, for example, MIR-1 (11 patients) (65), a BIL-1(CMY-2)-like enzyme (5 patients) (59), ACC-1 (13 patients) (60), and ACT-1 (17 patients) (13).

SUSCEPTIBILITY PATTERNS

Table 2 illustrates in vitro susceptibilities for *E. coli* transconjugants or transformants producing plasmid-mediated AmpC β -lactamases. Some of the MICs for what ought to be similar enzymes differ by more than can be attributed to experimental variation (e.g., LAT-1 and LAT-4 with cefotaxime, ceftazidime, or aztreonam) and may have resulted from differences in host *E. coli* strains. Strains with plasmid-mediated AmpC enzymes were consistently resistant to aminopenicillins (ampicillin or amoxicillin), carboxypenicillins (carbenicillin or ticarcillin), and ureidopenicillins (piperacillin) and, among the penicillins, these strains were susceptible only to amdinocillin or temocillin. The enzymes provided resistance to cephalosporins in the oxyimino group (ceftazidime, cefotaxime, ceftriaxone, ceftizoxime, cefuroxime) and the 7- α -methoxy group (cefoxitin, cefotetan, cefmetazole, moxalactam). MICs were usually higher for ceftazidime than for cefotaxime and for cefoxitin than for cefotetan. The enzymes were also active against the monobactam aztreonam, although for some strains

TABLE 2. In vitro susceptibilities (MIC) of *E. coli* derivatives producing plasmid-encoded AmpC β -lactamase

Anti-microbial agent	MIC (μ g/ml) (reference no.) for derivatives producing:																		
	ACC-1 (7)	ACT-1 (13)	BIL-1 (CMY-2) ^a (66, 88)	CMY-1 (9)	CMY-2 (8)	CMY-3 (14)	CMY-4 (85)	CMY-5 (90)	CMY-8 (91)	DHA-1 (26)	DHA-2 (24)	FOX-1 (31)	FOX-2 (10)	FOX-3 (51)	FOX-4 (12)	LAT-1 (CMY-2) ^a (83)	LAT-2 (CMY-2) ^a (28)	LAT-3 (29)	LAT-4 (LAT-1) ^a (29)
Ampicillin ^b			64	2,048		1,024	>128		>256	>512	>512			1,024	256	>128			1,000
Carbenicillin ^c			128			1,024	>128			128	128	>2,048		\geq 1,024	512	>128			128
Piperacillin	32	32	64	128	64		64			128	64	8			16				64
Temocillin	4			8	8					4									4
Mecillinam																			
Cephalexin ^d						>1,028													
Cefotaxime	8	\leq 2	8	64	16	16	16	64	>256	64	4	128	16	1	64	128	64	96	4
Ceftazidime	32	4	>16	4	128	16	8	256	32-64	64	8	2	32	16	>128	>128	>256	128	64
Cefoxitin	4	>256		256	256	128	8		>256	128	16	128	256	64	>512	64	256	256	8
Cefotetan	2	16		128	64	32	32					32	64		128	128			>512
Cefmetazole				8	2					0.5	2	4	1		32				\geq 64
Moxalactam	1	4	4	16	64	32	0.06	64		16	0.03	1	1	1	64	64	64	8	128
Aztreonam	0.25	\leq 0.06		0.25	0.5		0.06			0.125	0.25	1	0.13	\leq 0.06	2	64		0.5	>512
Cefepime	1			2	0.5						0.25								1
Ceftipime	0.13	1		0.25	0.5	0.25	0.25	0.5-1	0.25-0.5	\leq 0.125	0.25	1	0.5	0.12	0.5	2		1	1
Imipenem				0.06	0.06										0.12				0.125
Meropenem	0.03											0.03							0.5

^a Revised identity is shown in parentheses.

^b Or amoxicillin.

^c Or ticarcillin.

^d Or cefazolin.

TABLE 3. Effect of β -lactamase inhibitors (MIC) on *E. coli* derivatives producing plasmid-mediated AmpC β -lactamases

Agent(s)	MIC (μg/ml) (reference no.) for derivatives producing:												
	ACC-1 ^a (60)	BIL-1 ^b (CMY-2) ^h (88)	CMY-1 ^c (9)	CMY-2 ^c (8)	CMY-3 ^b (14)	DHA-1 ^d (26)	DHA-2 ^a (24)	FOX-1 ^e (31)	FOX-2 ^b (10)	FOX-3 ^d (51)	FOX-4 ^d (12)	LAT-1 (81, 83)	MIR-1 ^d (65, 81)
Ampicillin or amoxicillin + Clavulanate	>128 >128	64 >32	2,048 128		1,024 1,024	>512 >512	>512			1,024 32	256 256	>128 >64 ^g	1,000 ≥256
Cefoxitin			256	256				128	256	64	>512		
+ Clavulanate			64	128				64	128	64	>512		
+ Sulbactam			32	32					32				
+ Tazobactam			64	64					128				
Cefotaxime		8	64							1	64		
+ Clavulanate		>4	16							1	64		
+ Sulbactam			16										
+ Tazobactam			32										
Ceftazidime		>16	4				8			16	>128	32	128
+ Clavulanate		>4	4				8			16	>128	32 ^d	128
+ Tazobactam												4 ^d	16
+ Ro 48-1220												0.5 ^d	2
Piperacillin	32		128	64			64						
+ Tazobactam	8		32	16			4						
Ticarcillin	256				1,024					≥1,024		>256	
+ Clavulanate	128				512					32		>128 ^g	

^a Clavulanate at 2 μ g/ml and tazobactam at 4 μ g/ml.^b Inhibitor concentration, 2 μ g/ml.^c In the proportions of 1:4 (clavulanate), 1:1 (sulbactam), and 1:7 (tazobactam).^d Inhibitor concentration, 4 μ g/ml.^e Inhibitor concentration, 5 μ g/ml.^f In the proportion of 1:4 (clavulanate), 1:2 (sulbactam), and 1:8 (tazobactam).^g Clavulanate at 2 μ g/ml with ticarcillin and in the proportion of 1:2 with ampicillin.^h Revised identity is shown in parentheses.

aztreonam MICs were in the susceptible range. Susceptibility to cefepime or cefpirome was little affected and was unchanged for carbapenems (imipenem, meropenem).

Alterations in antibiotic access to the enzyme can markedly change the susceptibility profile. With loss of outer membrane porin channels, *K. pneumoniae* strains carrying plasmids determining AmpC enzymes can have imipenem MICs as high as 64 μ g/ml and meropenem MICs of 16 μ g/ml (53). In such strains, MICs of cefepime and cefpirome become inoculum dependent, and at inocula of 10^7 /ml MICs can exceed 256 μ g/ml (53). Clinical isolates of *K. pneumoniae* and *E. coli* with imipenem

MICs from 16 to 64 μ g/ml through porin loss and carriage of ACT-1 (13) or CMY-4 (17, 78) have already been reported and are a cause for concern.

The effects of β -lactamase inhibitors on susceptibility is summarized in Table 3. Although commercially available inhibitors, especially sulbactam, caused a modest reduction in MICs of cefoxitin, *E. coli* derivatives with plasmid-mediated AmpC enzymes were not susceptible to inhibitor combinations, with the possible exception of piperacillin-tazobactam. Resistance was, however, blocked by BRL 42715 (7, 19, 53), Ro 47-8284 (7), Ro 48-1256 (50), or Ro 48-1220 (81).

TABLE 4. Substrate profile (V_{\max} relative to cephaloridine) of plasmid-determined AmpC β -lactamases

Agent	V_{\max} (reference no.)												
	ACC-1 (7)	ACT-1 (13)	CMY-3 (14)	DHA-1 (26)	FOX-1 ^c (31)	FOX-3 (51)	FOX-4 (12)	LAT-1 (83)	LAT-2 (CMY-2) ^d (28)	LAT-3 (29)	LAT-4 (LAT-1) ^d (29)	MIR-1 (65)	MOX-1 (36)
Benzylpenicillin		7.1	5	67	1.3	1.2		5	3	4	5	4	
Ampicillin ^a			1	3			0.2	1	1	2	2	1	40
Carbenicillin ^b			<0.1					<1				<1	
Cephalothin			110	262	371	320		130	169	138	140	122	
Cefoxitin	<0.01	0.11	<0.1		0.74	<1	3.3	<1				<1	
Cefotetan	<0.01	0.014											8.3
Ceftazidime	\leq 0.1		<0.1	2		<1	0.25	1	2.2	2	2	3	1.5
Cefotaxime	<0.02	0.006	<0.1	<1		<1	0.09	<1	1	<1	<1	10	201
Moxalactam			<0.1	<1									2.4
Aztreonam		<0.1	<0.1	<1		<1							80

^a Or amoxicillin.^b Or ticarcillin.^c Values shown are for pI 6.8 variant. pI 7.2 variant gave similar results.^d Revised identity is shown in parentheses.

TABLE 5. Affinity constants (K_m) of plasmid-encoded AmpC β -lactamases

Agent	K_m (μ M) (reference no.)								
	ACC-1 (7)	ACT-1 (13)	BIL-1 ^a (CMY-2) ^c (66)	CMY-3 (14)	FOX-1 ^b (31)	FOX-3 (51)	FOX-4 (12)	LAT-2 (CMY-2) ^c (28)	MOX-1 (36)
Benzylpenicillin		10		3	43	36		12	
Ampicillin			8.7				23	17	2.4
Cephalothin				40	224	187		55	
Cephaloridine	122	380		90	375	363	1,400	10	134
Cefoxitin		3.7		0.2	1.3		37		
Cefotetan		2.5							805
Cefotaxime		7	0.01	0.5			1.2		1,064
Ceftazidime	17		20	115			14		2.7
Moxalactam				0.005					1.7
Aztreonam				0.01					40
Cefepime		1,040							
Imipenem		7.5							

^a K_i values with nitrocefin as substrate.^b Values shown are for pI 6.8 variant; pI 7.2 variant gave similar results.^c Revised identity is shown in parentheses.

DETECTION

In bacterial species without an inducible AmpC-type β -lactamase, appearance of a susceptibility pattern typical of an *Enterobacter* or *C. freundii* isolate that overproduces its chromosomal β -lactamase is highly suggestive of a plasmid-encoded AmpC-type enzyme (56, 67). Unfortunately, other mechanisms can produce a similar resistance phenotype. In *E. coli* hyperproduction of chromosomal AmpC together with OmpF porin loss (52), or in *K. pneumoniae* porin deficiency alone (33), can give cephamycin and oxymino- β -lactam resistance. Furthermore, not all strains with plasmid-mediated AmpC enzymes meet the NCCLS criteria for resistance to cephamycins and oxymino-cephalosporins. For example, *E. coli* with ACC-1 can be resistant to ceftazidime but not cefoxitin or cefotetan, while a strain with DHA-2 was intermediate in resistance to cefoxitin but susceptible to cefotaxime or ceftazidime (Table 2). Suspected isolates can be studied further for cephamycin hydrolysis with the three-dimensional test (20, 80) or the Masuda bioassay (65) and for β -lactamase inhibitor effects. Unfortunately, inhibitors (BRL 42715, Ro 47-8284, Ro 48-1220, Ro 48-1256) that are active against AmpC enzymes are not readily available, but cloxacillin (69) or cefoxitin (65) have been used to block AmpC activity selectively after isoelectric focusing. Lack of inhibition of activity against oxy-

imino- β -lactams or cephamycins by clavulanate is indirect evidence for the presence of an AmpC enzyme, but some AmpC enzymes are unusually susceptible to inhibition by tazobactam (1). A reference laboratory is needed for β -lactamase isoelectric focusing or gene localization. Detecting a plasmid-mediated AmpC enzyme in a strain with a native inducible β -lactamase or a coexisting ESBL is even more challenging.

Given the difficulty in detecting plasmid-mediated AmpC β -lactamases, their prevalence is currently likely to be underestimated. Coudron et al. studied 1,286 consecutive, nonrepeat isolates from a single VA Medical Center collected between 1995 and 1997 and estimated that 1.6% of *E. coli* isolates, 1.1% of *K. pneumoniae* isolates, and 0.4% of *P. mirabilis* isolates were cefoxitin-resistant AmpC β -lactamase producers, mostly via transmissible plasmids (20).

ENZYMATIC PROPERTIES

Plasmid-mediated AmpC-type β -lactamases have pIs between 6.4 and 9.4 (Table 1). Several of the FOX-type enzymes show multiple satellite bands (31). In clinical isolates containing several β -lactamases, AmpC enzymes can be identified after isoelectric focusing by differential inhibition of nitrocefin reactivity with 5 mg of cefoxitin/ml (65) or detection of cefoxitin hydrolysis by bioassay (10). A few plasmids carry *ampR* as

TABLE 6. Inhibition profiles of plasmid-determined AmpC β -lactamases

Agent	50% inhibitory concn (μ M) (reference no.)											
	ACT-1 (13)	BIL-1 (CMY-2) ^b (66)	CMY-3 ^a (14)	DHA-1 (26)	FOX-1 (31)	FOX-3 (51)	LAT-1 (28, 81, 83)	LAT-2 (CMY-2) ^b (28)	LAT-3 (29)	LAT-4 (LAT-1) ^b (29)	MIR-1 (65)	MOX-1 ^a (36)
Aztreonam				0.06	0.020	0.0015	0.03	0.02				
Cefoxitin		4.1					0.8	0.65			0.006	
Clavulanate	52	362	140	>100	>1	3	>250	250	>100	>100	0.21	5.6
Cloxacillin				0.1	0.023	0.02	0.001					0.35
Ro 48-1220							0.8		0.7	0.8		
Sulbactam	2.6	18	10						48	50		
Tazobactam	1.3	3.2	10	0.6			13		12	12	0.008	
Ticarcillin				0.01								

^a Value shown is K_i instead of 50% inhibitory concentration.^b Revised identity is shown in parentheses.




FIG. 1. Dendrogram for chromosomal and plasmid-encoded AmpC β -lactamases, calculated by Clustal X (34) and the neighbor-joining method (73). Branch lengths are proportional to the number of amino acid exchanges. GenBank accession numbers for *bla*_{AmpC} can be found at http://www.rochester.edu/College/BIO/labs/HallLab/AmpC_Phylo.html.

well as *ampC* genes and are inducible (DHA-1 and DHA-2) (3, 24), but most plasmid-mediated *ampC* genes are expressed constitutively, for example, MIR-1, even in the presence of a complete system for induction (41).

The apparent molecular size of the mature plasmid-mediated AmpC β -lactamases vary from 38 to 42 kDa with 378 (3), 381 (8, 29, 41), 382 (10, 37), or 386 (7) amino acid residues. Kinetic properties were characteristic of chromosomal AmpC enzymes with relative V_{\max} values generally 10-fold or more greater for cephalothin and cephaloridine than for ampicillin and penicillin, greater activity with penicillin than with ampicillin, and low hydrolysis rates for oxymino- or α -methoxy-compounds (Table 4). On the other hand, K_m values for cefoxitin, cefotetan, cefotaxime, moxalactam, or aztreonam were generally less than those for penicillin or ampicillin and much lower than the K_m values for cephaloridine, cephalothin, or cefepime (Table 5).

As is typical of group 1 cephalosporinases (16), plasmid-mediated AmpC enzymes were inhibited by low concentrations of aztreonam, cefoxitin, or cloxacillin and only by high concentrations of clavulanate (Table 6). Sulbactam and particularly tazobactam were more effective inhibitors but were an order of magnitude less potent than Ro 48-1220.

The amino acid sequence of the enzymes revealed an active-site serine in the motif Ser-X-X-Lys (where X is any amino acid) at residues 64 to 67 of the mature protein. A Lys-Ser/Thr-Gly motif has been found at residues 315 to 317 and plays an essential role in forming the tertiary structure of the active site. A tyrosine residue at position 150 forms part of the class C-typical motif Tyr-X-Asn and is also important (but not essential) for catalysis of β -lactam hydrolysis (21, 64).

A dendrogram of chromosomal and plasmid-encoded AmpC enzymes (Fig. 1) demonstrates the diversity of chromosomal AmpC genes and the close relationship of some plasmid-mediated enzymes to chromosomal enzymes of particular organisms. The plasmid-mediated enzymes can be divided into five or six clusters: the *C. freundii* group with LAT types and certain CMY types, the *Enterobacter* group with MIR-1 and ACT-1, the *M. morganii* group with DHA-1 and DHA-2, the *H. alvei* group represented by ACC-1, and the *Aeromonas* group with MOX-, FOX-, and other CMY-type enzymes. The relationship between plasmid-encoded enzymes and certain chromosomal β -lactamases is very close: there is 100% amino acid homology within the *M. morganii* and *H. alvei* groups and more than 94% homology within the *C. freundii* group. ACT-1 and MIR-1 share 91.4% amino acid identity with each other but




FIG. 2. Comparative genetic organization of plasmid-encoded *ampC* genes related to the chromosomal β -lactamase gene of *C. freundii*. Adjacent nucleotide homology is that available for each gene and may be more extensive if carried further.

only 85 to 87% identity with most *E. cloacae* AmpC enzymes. However, the enzyme from *E. cloacae* strain GN7471 (47) has 91.1% identity to ACT-1 and MIR-1, and an environmental strain of *Enterobacter* was 98% identical (M. Rottman and G. Arlet, personal communication), so that origin from some *Enterobacter* species is likely. FOX enzymes have 95% or more sequence identity within the group, and CMY-1, CMY-8, and CMY-9 are more than 97% identical, but either group has only about 74% identity with the available *Aeromonas sobria* AmpC sequences, which in turn differ from each other by fully 25%. The AmpC sequence of *P. aeruginosa* is even more distant, so the origin of these enzymes remains uncertain.

Unlike ESBLs, which differ from their parent enzymes by amino acid substitutions that alter the properties of the active site (45), remodeling seems not to be necessary for the success of a plasmid-mediated AmpC enzyme. M. Barlow and B. G. Hall (submitted) found that chromosomal *ampC* genes from

C. freundii strains isolated in the 1920s were just as effective in providing β -lactam resistance as plasmid-mediated *ampC* alleles such as CMY-2 or LAT-3 when all were cloned into a common vector in a common *E. coli* host. Nonetheless, once a *bla*_{AmpC} gene is plasmid-borne further evolution may occur. For example, a naturally occurring Asn→Ile substitution at position 346 in CMY-1 has been reported to increase the ceftazidime MIC for a strain with the variant enzyme by four- to eightfold (A. Bauernfeind, I. Schneider, D. Meyer, R. Jungwirth, Y. Chong, and K. Lee, Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C-203, 1997). It is likely that in time other such changes will be observed, since a variety of genetic changes can improve the activity of the chromosomal AmpC enzyme of *E. cloacae* to particular substrates, such as activity toward cefuroxime and ceftazidime with a tandem duplication of three amino acids at positions 208 to 210 (63) or toward cefepime and ceftipime with an amino acid




FIG. 3. Structure of the integron coding for DHA-1 β -lactamase in pSAL-1 and its relationship to genes on the chromosome of *M. morganii*.




FIG. 4. Comparison of the sequence between common regions of In7, In6, pSAL-1 (DHA-1), pROT (DHA-1), pGC-2 (FOX-4), pMVP-1 (CMY-1), pKPW142 (CMY-8), and pRMOX-1 (MOX-1).

substitution at position 318 (58) or a deletion of six amino acids at residues 289 to 294 (4).

GENETIC FEATURES

Genes for the AmpC enzymes have been located on plasmids of sizes varying from 7 to 180 kb (37, 78). A few of the plasmids have not been self-transmissible but are transferable by transformation (65, 78, 89) or mobilization (28, 29, 82, 83). Plasmids encoding AmpC enzymes often carry multiple other resistances, including resistance to aminoglycosides, chloramphenicol, sulfonamide, tetracycline, trimethoprim, or mercuric ion (9, 10, 13, 65, 78). A plasmid encoding a FOX-type enzyme even carried a gene for fluoroquinolone resistance (54). Clinical isolates often produce other β -lactamases in addition to an AmpC enzyme. The *bla* genes may be on different plasmids, but often they coexist on the same plasmid. For example, the gene for ACT-1 was found in clinical isolates along with a pI 5.6 β -lactamase consistent with TEM-10 or TEM-26 and a pI 7.6 enzyme consistent with SHV-1, and on cloning the ACT-1 gene was found in a 15-kb cluster with genes for a β -lactamase of pI 5.4, presumably TEM-1, and pI 7.0, possibly another SHV-type enzyme (13). Furthermore, an ACT-1 probe hybridized to chromosomal DNA of these clinical strains, implying mobility of the gene by carriage on a transposon. Indirect evidence suggests that CMY-3 and CMY-4 could be transpo-

son-mediated as well: CMY-3 because its gene is located on the chromosome of a species (*P. mirabilis*) lacking a native AmpC gene (14), and CMY-4 because in *E. coli* clinical isolates from London a CMY-4 probe hybridized to both 7-kb and 45-kb plasmids, a dual location that could be explained by transposability (78). The MIR-1 gene is located near a sequence closely related to an insertion sequence transposase, but direct attempts to demonstrate transposability of MIR-1 or BIL-1 (CMY-2) have not been successful (25, 41).

The *C. freundii*-type *bla*_{CMY-5} gene has been mapped in plasmid pTKH11 to be adjacent to the *blc* and *sugE* genes found downstream from *ampC* on the *C. freundii* chromosome (89). The *ampR* gene upstream from *ampC* on the chromosome is missing and its place has been taken by a putative insertion element which could have been involved in gene capture. So far as they have been sequenced, other plasmids encoding *C. freundii*-type AmpC enzymes have a similar organization (Fig. 2), suggesting a direct derivation from the *C. freundii* chromosome with subsequent accumulation of mutations in the *ampC* gene to produce the present array of CMY- and LAT-type enzymes, a conclusion also supported by phylogenetic analysis (M. Barlow and B. G. Hall, submitted).

Many resistance genes, including those for Ambler class A, B, and D β -lactamases, are located in gene cassettes with a downstream 59-base element that acts as a specific recombi-

nation site for incorporation into integrons (32). Analysis of published sequences indicates that AmpC genes found on plasmids are not linked to 59-base elements. The DHA-1 structural and regulatory genes on plasmid pSAL-1, however, are present in an integron (Fig. 3) which includes a site-specific integrase, two copies of *qacEΔ1sull*, an *aadA2* gene for aminoglycoside resistance with its downstream 59-base element, and ORF341, a postulated recombinase (84). The genetic organization of this integron is similar to In6 and In7 found in plasmids pSa and pDGO100, which lack *bla* genes (79). *ampC* and *ampR* genes from the chromosome of *M. morganii* (2, 70) thus appear to have inserted into a complex *sulI*-type integron. Since no downstream 59-base element remains, either it was deleted or integration involved another mechanism. Verdet et al. identified a 50-bp sequence near *bla*_{DHA-1} that is present also in In6 and In7. A virtually identical sequence occurs near genes for FOX-4, CMY-1, CMY-8, and MOX-1 (Fig. 4). Such a sequence could represent a recombination site different from the 59-base element. Further study of the structure of plasmids carrying *ampC* genes is likely to reveal additional tricks used by bacteria to mobilize genes for dissemination.

CONCLUSIONS

Among gram-negative bacteria, the emergence of resistance to expanded-spectrum cephalosporins has been a major concern, initially in a limited number of bacterial species (*E. cloacae*, *C. freundii*, *S. marcescens*, and *P. aeruginosa*) that could mutate to hyperproduce their chromosomal class C β-lactamase. A few years later, resistance appeared in bacterial species not naturally producing AmpC enzymes (*K. pneumoniae*, *Salmonella* spp., *P. mirabilis*) due to the production of TEM- or SHV-type ESBLs. Characteristically, such resistance has included oxyimino- but not 7-α-methoxy-cephalosporins, has been blocked by inhibitors such as clavulanate, sulbactam, or tazobactam, and did not involve carbapenems. Plasmid-mediated AmpC β-lactamases represent a new threat since they confer resistance to 7-α-methoxy-cephalosporins such as cefoxitin or cefotetan, are not affected by commercially available β-lactamase inhibitors, and can, in strains with loss of outer membrane porins, provide resistance to carbapenems. This resistance mechanism has been found around the world, can cause nosocomial outbreaks, appears to be increasing in prevalence, and merits further study to define the best options for detection and treatment.

ADDENDUM

The sequence of ORF341 has recently been revised, extending the open reading frame to 1,541 nucleotides that encode a protein of 513 amino acids; this sequence has been renamed ORF 513 (GenBank accession no. L06418).

REFERENCES

- Babini, G. S., F. Danel, S. D. Munro, P. A. Micklesen, and D. M. Livermore. 1998. Unusual tazobactam-sensitive AmpC β-lactamase from two *Escherichia coli* isolates. *J. Antimicrob. Chemother.* **41**:115–118.
- Barnaud, G., G. Arlet, C. Danglot, and A. Philippon. 1997. Cloning and sequencing of the gene encoding the AmpC β-lactamase of *Morganella morganii*. *FEMS Microbiol. Lett.* **148**:15–20.
- Barnaud, G., G. Arlet, C. Verdet, O. Gaillot, P. H. Lagrange, and A. Philippon. 1998. *Salmonella enteritidis*: AmpC plasmid-mediated inducible β-lactamase (DHA-1) with an *ampR* gene from *Morganella morganii*. *Antimicrob. Agents Chemother.* **42**:2352–2358.
- Barnaud, G., R. Labia, L. Raskine, M. J. Sanson-Le Pors, A. Philippon, and G. Arlet. 2001. Extension of resistance to cefepime and ceftiofur associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an *Enterobacter cloacae* clinical isolate. *FEMS Microbiol. Lett.* **195**:185–190.
- Bauernfeind, A., Y. Chong, and K. Lee. 1998. Plasmid-encoded AmpC β-lactamases: how far have we gone 10 years after the discovery. *Yonsei Med. J.* **39**:520–525.
- Bauernfeind, A., Y. Chong, and S. Schweighart. 1989. Extended broad spectrum β-lactamase in *Klebsiella pneumoniae* including resistance to cephamycins. *Infection* **17**:316–321.
- Bauernfeind, A., I. Schneider, R. Jungwirth, H. Sahly, and U. Ullmann. 1999. A novel type of AmpC β-lactamase, ACC-1, produced by a *Klebsiella pneumoniae* strain causing nosocomial pneumonia. *Antimicrob. Agents Chemother.* **43**:1924–1931.
- Bauernfeind, A., I. Stemmlinger, R. Jungwirth, and H. Giamarellou. 1996. Characterization of the plasmidic β-lactamase CMY-2, which is responsible for cephamycin resistance. *Antimicrob. Agents Chemother.* **40**:221–224.
- Bauernfeind, A., I. Stemmlinger, R. Jungwirth, R. Wilhelm, and Y. Chong. 1996. Comparative characterization of the cephalosporinase *bla*_{CMY-1} gene and its relationship with other β-lactamase genes. *Antimicrob. Agents Chemother.* **40**:1926–1930.
- Bauernfeind, A., S. Wagner, R. Jungwirth, I. Schneider, and D. Meyer. 1997. A novel class C β-lactamase (FOX-2) in *Escherichia coli* conferring resistance to cephamycins. *Antimicrob. Agents Chemother.* **41**:2041–2046.
- Bobrowski, M. M., M. Matthew, P. T. Barth, N. Datta, N. J. Grinter, A. E. Jacob, P. Kontomichalou, J. W. Dale, and J. T. Smith. 1976. Plasmid-determined β-lactamase indistinguishable from the chromosomal β-lactamase of *Escherichia coli*. *J. Bacteriol.* **125**:149–157.
- Bou, G., A. Oliver, M. Ojeda, C. Monzón, and J. Martínez-Beltrán. 2000. Molecular characterization of FOX-4, a new AmpC-type plasmid-mediated β-lactamase from an *Escherichia coli* strain isolated in Spain. *Antimicrob. Agents Chemother.* **44**:2549–2553.
- Bradford, P. A., C. Urban, N. Mariano, S. J. Projan, J. J. Rahal, and K. Bush. 1997. Imipenem resistance in *Klebsiella pneumoniae* is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the loss of an outer membrane protein. *Antimicrob. Agents Chemother.* **41**:563–569.
- Bret, L., C. Chanal-Claris, D. Sirot, E. B. Chaibi, R. Labia, and J. Sirot. 1998. Chromosomally encoded ampC-type β-lactamase in a clinical isolate of *Proteus mirabilis*. *Antimicrob. Agents Chemother.* **42**:1110–1114.
- Brun-Buisson, C., P. Legrand, A. Philippon, F. Montravers, M. Ansquer, and J. Duval. 1987. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant *Klebsiella pneumoniae*. *Lancet* **ii**:302–306.
- Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. *Antimicrob. Agents Chemother.* **39**:1211–1233.
- Cao, V. T., G. Arlet, B. M. Ericsson, A. Tammelin, P. Courvalin, and T. Lambert. 2000. Emergence of imipenem resistance in *Klebsiella pneumoniae* owing to combination of plasmid-mediated CMY-4 and permeability alteration. *J. Antimicrob. Chemother.* **46**:895–900.
- Caroff, N., E. Espaze, D. Gautreau, H. Richet, and A. Reynaud. 2000. Analysis of the effects of –42 and –32 *ampC* promoter mutations in clinical isolates of *Escherichia coli* hyperproducing AmpC. *J. Antimicrob. Chemother.* **45**:783–788.
- Coleman, K., D. R. Griffin, J. W. Page, and P. A. Upshon. 1989. In vitro evaluation of BRL 42715, a novel β-lactamase inhibitor. *Antimicrob. Agents Chemother.* **33**:1580–1587.
- Coudron, P. E., E. S. Moland, and K. S. Thomson. 2000. Occurrence and detection of AmpC β-lactamases among *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis* isolates at a Veterans' Medical Center. *J. Clin. Microbiol.* **38**:1791–1796.
- Dubus, A., S. Normark, M. Kania, and M. G. P. Page. 1994. The role of tyrosine 150 in catalysis of β-lactam hydrolysis by AmpC β-lactamase from *Escherichia coli* investigated by site-directed mutagenesis. *Biochemistry* **33**:8577–8586.
- Dunne, E. F., P. D. Fey, P. Kludt, R. Reporter, F. Mostashari, P. Shillam, J. Wicklund, C. Miller, B. Holland, K. Stamey, T. J. Barrett, J. K. Rasheed, F. C. Tenover, E. M. Ribot, and F. J. Angulo. 2000. Emergence of domestically acquired ceftriaxone-resistant *Salmonella* infections associated with AmpC β-lactamase. *JAMA* **284**:3151–3156.
- Fey, P. D., T. J. Safraneck, M. E. Rupp, E. F. Dunne, E. I. P. C. Ribot, P. A. Bradford, F. J. Angulo, and S. H. Hinrichs. 2000. Ceftriaxone-resistant salmonella infection acquired by a child from cattle. *N. Engl. J. Med.* **342**:1242–1249.
- Fortineau, N., L. Poirel, and P. Nordmann. 2001. Plasmid-mediated and inducible cephalosporinase DHA-2 from *Klebsiella pneumoniae*. *J. Antimicrob. Chemother.* **47**:207–210.
- Fosberry, A. P., D. J. Payne, E. J. Lawlor, and J. E. Hodgson. 1994. Cloning and sequence analysis of *bla*_{BIL-1}, a plasmid-mediated class C β-lactamase in *Escherichia coli* BS. *Antimicrob. Agents Chemother.* **38**:1182–1185.
- Gaillot, O., C. Clement, M. Simonet, and A. Philippon. 1997. Novel transferable β-lactam resistance with cephalosporinase characteristics in *Salmo-*

- nella enteritidis*. J. Antimicrob. Chemother. **39**:85–87.
27. Gazouli, M., M. E. Kaufmann, E. Tzelepi, H. Dimopoulou, O. Paniara, and L. S. Tzouvelekis. 1997. Study of an outbreak of cefoxitin-resistant *Klebsiella pneumoniae* in a general hospital. J. Clin. Microbiol. **35**:508–510.
 28. Gazouli, M., L. S. Tzouvelekis, E. Prinarakis, V. Miriagou, and E. Tzelepi. 1996. Transferable cefoxitin resistance in enterobacteria from Greek hospitals and characterization of a plasmid-mediated group 1 β -lactamase (LAT-2). Antimicrob. Agents Chemother. **40**:1736–1740.
 29. Gazouli, M., L. S. Tzouvelekis, A. C. Vatopoulos, and E. Tzelepi. 1998. Transferable class C β -lactamases in *Escherichia coli* strains isolated in Greek hospitals and characterization of two enzyme variants (LAT-3 and LAT-4) closely related to *Citrobacter freundii* AmpC β -lactamase. J. Antimicrob. Chemother. **42**:419–425.
 30. Girlich, D., A. Karim, C. Spicq, and P. Nordmann. 2000. Plasmid-mediated cephalosporinase ACC-1 in clinical isolates of *Proteus mirabilis* and *Escherichia coli*. Eur. J. Clin. Microbiol. Infect. Dis. **19**:893–895.
 31. Gonzalez Leiza, M., J. C. Perez-Diaz, J. Ayala, J. M. Casellas, J. Martinez-Beltran, K. Bush, and F. Baquero. 1994. Gene sequence and biochemical characterization of FOX-1 from *Klebsiella pneumoniae*, a new AmpC-type plasmid-mediated β -lactamase with two molecular variants. Antimicrob. Agents Chemother. **38**:2150–2157.
 32. Hall, R. M., and C. M. Collis. 1998. Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons. Drug Resist. Updates **1**:109–119.
 33. Hernández-Allés, S., M. C. Conejo, A. Pascual, J. M. Tomás, V. J. Benedí, and L. Martínez-Martínez. 2000. Relationship between outer membrane alterations and susceptibility to antimicrobial agents in isogenic strains of *Klebsiella pneumoniae*. J. Antimicrob. Chemother. **46**:273–277.
 34. Higgins, D. G., A. J. Bleasby, and R. Fuchs. 1992. CLUSTAL V: improved software for multiple sequence alignment. Comput. Appl. Biosci. **8**:189–191.
 35. Honoré, N., M. H. Nicolas, and S. T. Cole. 1986. Inducible cephalosporinase production in clinical isolates of *Enterobacter cloacae* is controlled by a regulatory gene that has been deleted from *Escherichia coli*. EMBO J. **5**:3709–3714.
 36. Horii, T., Y. Arakawa, M. Ohta, S. Ichiyama, R. Wacharotayankun, and N. Kato. 1993. Plasmid-mediated AmpC-type β -lactamase isolated from *Klebsiella pneumoniae* confers resistance to broad-spectrum β -lactams, including moxalactam. Antimicrob. Agents Chemother. **37**:984–990.
 37. Horii, T., Y. Arakawa, M. Ohta, T. Sugiyama, R. Wacharotayankun, H. Ito, and N. Kato. 1994. Characterization of a plasmid-borne and constitutively expressed *bla*_{MOX-1} gene encoding AmpC-type β -lactamase. Gene **139**:93–98.
 38. Jacobs, C., J.-M. Frère, and S. Normark. 1997. Cytosolic intermediates for cell wall biosynthesis and degradation control inducible β -lactam resistance in gram-negative bacteria. Cell **88**:823–832.
 39. Jacoby, G. A. 1994. Genetics of extended-spectrum beta-lactamases. Eur. J. Clin. Microbiol. Infect. Dis. **13**(Suppl. 1):2–11.
 40. Jacoby, G. A., and A. A. Medeiros. 1991. More extended-spectrum β -lactamases. Antimicrob. Agents Chemother. **35**:1697–1704.
 41. Jacoby, G. A., and J. Tran. 1999. Sequence of the MIR-1 β -lactamase gene. Antimicrob. Agents Chemother. **43**:1759–1760.
 42. Jaurin, B., T. Grundström, T. Edlund, and S. Normark. 1981. The *E. coli* β -lactamase attenuator mediates growth rate-dependent regulation. Nature **290**:221–225.
 43. Jenks, P. J., Y. M. Hu, F. Danel, S. Mehtar, and D. M. Livermore. 1995. Plasmid-mediated production of class I (AmpC) β -lactamase by two *Klebsiella pneumoniae* isolates from the UK. J. Antimicrob. Chemother. **35**:235–236.
 44. Knothe, H., P. Shah, V. Krcmery, M. Antal, and S. Mitsuhashi. 1983. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of *Klebsiella pneumoniae* and *Serratia marcescens*. Infection **11**:315–317.
 45. Knox, J. R. 1995. Extended-spectrum and inhibitor-resistant TEM-type β -lactamases: mutations, specificity, and three-dimensional structure. Antimicrob. Agents Chemother. **39**:2593–2601.
 46. Koeck, J. L., G. Arlet, A. Philippon, S. Basmaciogullari, H. V. Thien, Y. Buisson, and J. D. Cavallo. 1997. A plasmid-mediated CMY-2 β -lactamase from an Algerian clinical isolate of *Salmonella senftenberg*. FEMS Microbiol. Lett. **152**:255–260.
 47. Kuga, A., R. Okamoto, and M. Inoue. 2000. *ampR* gene mutations that greatly increase class C β -lactamase activity in *Enterobacter cloacae*. Antimicrob. Agents Chemother. **44**:561–567.
 48. Levesque, R., P. H. Roy, R. Letarte, and J. C. Pechère. 1982. A plasmid-mediated cephalosporinase from *Achromobacter* species. J. Infect. Dis. **145**:753–761.
 49. Livermore, D. M. 1995. β -lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. **8**:557–584.
 50. Livermore, D. M., and M. Yuan. 1996. Antibiotic resistance and production of extended-spectrum β -lactamases amongst *Klebsiella* spp. from intensive care units in Europe. J. Antimicrob. Chemother. **38**:409–424.
 51. Marchese, A., G. Arlet, G. C. Schito, P. H. Lagrange, and A. Philippon. 1998. Characterization of FOX-3, an AmpC-type plasmid-mediated β -lactamase from an Italian isolate of *Klebsiella oxytoca*. Antimicrob. Agents Chemother. **42**:464–467.
 52. Martínez-Martínez, L., M. C. Conejo, A. Pascual, S. Hernández-Allés, S. Ballesta, E. Ramírez De Arellano-Ramos, V. J. Benedí, and E. J. Perea. 2000. Activities of imipenem and cephalosporins against clonally related strains of *Escherichia coli* hyperproducing chromosomal β -lactamase and showing altered porin profiles. Antimicrob. Agents Chemother. **44**:2534–2536.
 53. Martínez-Martínez, L., A. Pascual, S. Hernández-Allés, D. Alvarez-Díaz, A. I. Suárez, J. Tran, V. J. Benedí, and G. A. Jacoby. 1999. Roles of β -lactamases and porins in activities of carbapenems and cephalosporins against *Klebsiella pneumoniae*. Antimicrob. Agents Chemother. **43**:1669–1673.
 54. Martínez-Martínez, L., A. Pascual, and G. A. Jacoby. 1998. Quinolone resistance from a transferable plasmid. Lancet **351**:797–799.
 55. Maurelli, A. T., R. E. Fernández, C. A. Bloch, C. K. Rode, and A. Fasano. 1998. “Black holes” and bacterial pathogenicity: a large genomic deletion that enhances the virulence of *Shigella* spp. and enteroinvasive *Escherichia coli*. Proc. Natl. Acad. Sci. USA **95**:3943–3948.
 56. Medeiros, A. 1997. Evolution and dissemination of β -lactamases accelerated by generations of β -lactam antibiotics. Clin. Infect. Dis. **24**:S19–S45.
 57. Morosini, M. I., J. A. Ayala, F. Baquero, J. L. Martínez, and J. Blázquez. 2000. Biological cost of AmpC production for *Salmonella enterica* serotype Typhimurium. Antimicrob. Agents Chemother. **44**:3137–3143.
 58. Morosini, M. I., M. C. Negri, B. Shoichet, M. R. Baquero, F. Baquero, and J. Blázquez. 1998. An extended-spectrum AmpC-type β -lactamase obtained by in vitro antibiotic selection. FEMS Microbiol. Lett. **165**:85–90.
 59. M’Zali, F. H., J. Heritage, D. M. Gascayne-Binzi, M. Denton, N. J. Todd, and P. M. Hawkey. 1997. Transcontinental importation into the UK of *Escherichia coli* expressing a plasmid-mediated AmpC-type β -lactamase exposed during an outbreak of SHV-5 extended-spectrum β -lactamase in a Leeds hospital. J. Antimicrob. Chemother. **40**:823–831.
 60. Nadjar, D., M. Rouveau, C. Verdet, J. Donay, J. Herrmann, P. H. Lagrange, A. Philippon, and G. Arlet. 2000. Outbreak of *Klebsiella pneumoniae* producing transferable AmpC-type β -lactamase (ACC-1) originating from *Hafnia alvei*. FEMS Microbiol. Lett. **187**:35–40.
 61. Naumovski, L., J. P. Quinn, D. Miyashiro, M. Patel, K. Bush, S. B. Singer, D. Graves, T. Palzkill, and A. M. Arvin. 1992. Outbreak of ceftazidime resistance due to a novel extended-spectrum β -lactamase in isolates from cancer patients. Antimicrob. Agents Chemother. **36**:1991–1996.
 62. Nelson, E. C., and B. G. Elisha. 1999. Molecular basis of AmpC hyperproduction in clinical isolates of *Escherichia coli*. Antimicrob. Agents Chemother. **43**:957–959.
 63. Nukaga, M., S. Haruta, K. Tanimoto, K. Kogure, K. Taniguchi, M. Tamaki, and T. Sawai. 1995. Molecular evolution of a class C β -lactamase extending its substrate specificity. J. Biol. Chem. **270**:5729–5735.
 64. Oefner, C., A. D’Arcy, J. J. Daly, K. Gubernator, R. L. Charnas, I. Heinze, C. Hubschwerlen, and F. K. Winkler. 1990. Refined crystal structure of β -lactamase from *Citrobacter freundii* indicates a mechanism for β -lactam hydrolysis. Nature **343**:284–288.
 65. Papanicolaou, G. A., A. A. Medeiros, and G. A. Jacoby. 1990. Novel plasmid-mediated β -lactamase (MIR-1) conferring resistance to oxymino- and α -methoxy β -lactams in clinical isolates of *Klebsiella pneumoniae*. Antimicrob. Agents Chemother. **34**:2200–2209.
 66. Payne, D. J., N. Woodford, and S. G. B. Amyes. 1992. Characterization of the plasmid mediated β -lactamase BIL-1. J. Antimicrob. Chemother. **30**:119–127.
 67. Philippon, A., G. Arlet, and P. H. Lagrange. 1994. Origin and impact of plasmid-mediated extended-spectrum beta-lactamases. Eur. J. Clin. Microbiol. Infect. Dis. **13**(Suppl. 1):17–29.
 68. Philippon, A., R. Labia, and G. Jacoby. 1989. Extended-spectrum β -lactamases. Antimicrob. Agents Chemother. **33**:1131–1136.
 69. Pitout, J. D., K. S. Thomson, N. D. Hanson, A. F. Ehrhardt, E. S. Moland, and C. C. Sanders. 1998. β -Lactamases responsible for resistance to expanded-spectrum cephalosporins in *Klebsiella pneumoniae*, *Escherichia coli*, and *Proteus mirabilis* isolates recovered in South Africa. Antimicrob. Agents Chemother. **42**:1350–1354.
 70. Poirer, L., M. Guibert, D. Girlich, T. Naas, and P. Nordmann. 1999. Cloning, sequence analyses, expression, and distribution of *ampC-ampR* from *Morganella morganii* clinical isolates. Antimicrob. Agents Chemother. **43**:769–776.
 71. Rhimi-Mahjoubi, F., M. Bernier, G. Arlet, Z. Ben Jemaa, P. Jouve, A. Hammami, and A. Philippon. Mise en évidence de la céphalosporinase plasmidique ACC-1 dans différentes entérobactéries (*Klebsiella pneumoniae*, *Proteus mirabilis*, *Salmonella*) isolées dans un hôpital Tunisien (Sfax, 1997–2000). Path. Biol., in press.
 72. Rice, L. B., S. H. Willey, G. A. Papanicolaou, A. A. Medeiros, G. M. Eliopoulos, R. C. Moellering, Jr., and G. A. Jacoby. 1990. Outbreak of ceftazidime resistance caused by extended-spectrum β -lactamases at a Massachusetts chronic-care facility. Antimicrob. Agents Chemother. **34**:2193–2199.
 73. Saitou, N., and M. Nei. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. **4**:406–425.
 74. Sanders, C. C. 1987. Chromosomal cephalosporinases responsible for mul-

- multiple resistance to newer β -lactam antibiotics. *Annu. Rev. Microbiol.* **41**:573–593.
75. Sanders, C. C. 1992. β -lactamases of gram-negative bacteria: new challenges for new drugs. *Clin. Infect. Dis.* **14**:1089–1099.
 76. Sanderson, K. E., A. Hessel, and K. E. Rudd. 1995. Genetic map of *Salmonella typhimurium*, edition VIII. *Microbiol. Rev.* **59**:241–303.
 77. Shannon, K. P., A. King, I. Phillips, M. H. Nicolas, and A. Philippon. 1990. Importation of organisms producing broad-spectrum SHV-group β -lactamases into the United Kingdom. *J. Antimicrob. Chemother.* **25**:343–351.
 78. Stapleton, P. D., K. P. Shannon, and G. L. French. 1999. Carbapenem resistance in *Escherichia coli* associated with plasmid-determined CMY-4 β -lactamase production and loss of an outer membrane protein. *Antimicrob. Agents Chemother.* **43**:1206–1210.
 79. Stokes, H. W., C. Tomaras, Y. Parsons, and R. M. Hall. 1993. The partial 3'-conserved segment duplications in the integrons In6 from pSa and In7 from pDGO100 have a common origin. *Plasmid* **30**:39–50.
 80. Thomson, K. S., and C. C. Sanders. 1992. Detection of extended-spectrum β -lactamases in members of the family *Enterobacteriaceae*: comparison of the double-disk and three-dimensional tests. *Antimicrob. Agents Chemother.* **36**:1877–1882.
 81. Tzouvelekis, L. S., M. Gazouli, E. E. Prinarakis, E. Tzelepi, and N. J. Legakis. 1997. Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48–1220 against β -lactamases that belong to groups 1, 2b, and 2be. *Antimicrob. Agents Chemother.* **41**:475–477.
 82. Tzouvelekis, L. S., E. Tzelepi, and A. F. Mentis. 1994. Nucleotide sequence of a plasmid-mediated cephalosporinase gene (*bla_{LAT-1}*) found in *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* **38**:2207–2209.
 83. Tzouvelekis, L. S., E. Tzelepi, A. F. Mentis, and A. Tsakris. 1993. Identification of a novel plasmid-mediated β -lactamase with chromosomal cephalosporinase characteristics from *Klebsiella pneumoniae*. *J. Antimicrob. Chemother.* **31**:645–654.
 84. Verdet, C., G. Arlet, G. Barnaud, P. H. Lagrange, and A. Philippon. 2000. A novel integron in *Salmonella enterica* serovar Enteritidis, carrying the *bla_(DHA-1)* gene and its regulator gene *ampR*, originated from *Morganella morganii*. *Antimicrob. Agents Chemother.* **44**:222–225.
 85. Verdet, C., G. Arlet, S. Ben Redjeb, A. Ben Hassen, P. H. Lagrange, and A. Philippon. 1998. Characterisation of CMY-4, an AmpC-type plasmid-mediated β -lactamase in a Tunisian clinical isolate of *Proteus mirabilis*. *FEMS Microbiol. Lett.* **169**:235–240.
 86. Wiedemann, B., H. Dietz, and D. Pfeifle. 1998. Induction of β -lactamase in *Enterobacter cloacae*. *Clin. Infect. Dis.* **27**(Suppl. 1):S42–S47.
 87. Winokur, P. L., A. Brueggemann, D. L. DeSalvo, L. Hoffmann, M. D. Apley, E. K. Uhlenhopp, M. A. Pfaller, and G. V. Doern. 2000. Animal and human multidrug-resistant, cephalosporin-resistant *Salmonella* isolates expressing a plasmid-mediated CMY-2 AmpC β -lactamase. *Antimicrob. Agents Chemother.* **44**:2777–2783.
 88. Woodford, N., D. J. Payne, A. P. Johnson, M. J. Weinbren, R. M. Perinpanayagam, R. C. George, B. D. Cookson, and S. G. B. Amyes. 1990. Transferable cephalosporin resistance not inhibited by clavulanate in *Escherichia coli*. *Lancet* **336**:253.
 89. Wu, S. W., K. Dornbusch, G. Kronvall, and M. Norgren. 1999. Characterization and nucleotide sequence of a *Klebsiella oxytoca* cryptic plasmid encoding a CMY-type β -lactamase: confirmation that the plasmid-mediated cephamycinase originated from the *Citrobacter freundii* AmpC β -lactamase. *Antimicrob. Agents Chemother.* **43**:1350–1357.
 90. Wu, S. W., K. Dornbusch, M. Norgren, and G. Kronvall. 1992. Extended spectrum β -lactamase from *Klebsiella oxytoca*, not belonging to the TEM or SHV family. *J. Antimicrob. Chemother.* **30**:3–16.
 91. Yan, J.-J., S.-M. Wu, S.-H. Tsai, J.-J. Wu, and I.-J. Su. 2000. Prevalence of SHV-12 among clinical isolates of *Klebsiella pneumoniae* producing extended-spectrum β -lactamases and identification of a novel AmpC enzyme (CMY-8) in Southern Taiwan. *Antimicrob. Agents Chemother.* **44**:1438–1442.